Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3196403,half-lives,Elimination from most of the organs occurred quite uniformly with half-lives of 40-70 h.,Pharmacokinetics of nisoldipine. Distribution to and elimination from tissues and organs following single or repeated administration of [14C]nisoldipine to rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196403/),h,40-70,2430,DB00401,Nisoldipine
,3196403,terminal half-life,The residues in the body after repeated administration were eliminated with a terminal half-life of about 10 days.,Pharmacokinetics of nisoldipine. Distribution to and elimination from tissues and organs following single or repeated administration of [14C]nisoldipine to rats and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196403/),d,10,2431,DB00401,Nisoldipine
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,3,9816,DB00401,Nisoldipine
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,10,9817,DB00401,Nisoldipine
,9126675,elimination half-lives,"The onset of action of verapamil, nifedipine, and diltiazem, at least in immediate-release formulations, is relatively fast (0.5-2 hours), and their elimination half-lives range from 2 to 7 hours.",Pharmacological aspects of calcium channel blockers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),h,2 to 7,9818,DB00401,Nisoldipine
,2471001,systemic clearance,"In the first infusion experiment, systemic clearance was 1.02 +/- 0.23 L/min (mean +/- SD), terminal half-life (t1/2) was 15.4 +/- 6.7 h, and volume of distribution was 5.9 +/- 1.8 L/kg.",Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471001/),[l] / [min],1.02,11580,DB00401,Nisoldipine
,2471001,terminal half-life (t1/2),"In the first infusion experiment, systemic clearance was 1.02 +/- 0.23 L/min (mean +/- SD), terminal half-life (t1/2) was 15.4 +/- 6.7 h, and volume of distribution was 5.9 +/- 1.8 L/kg.",Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471001/),h,15.4,11581,DB00401,Nisoldipine
,2471001,volume of distribution,"In the first infusion experiment, systemic clearance was 1.02 +/- 0.23 L/min (mean +/- SD), terminal half-life (t1/2) was 15.4 +/- 6.7 h, and volume of distribution was 5.9 +/- 1.8 L/kg.",Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2471001/),[l] / [kg],5.9,11582,DB00401,Nisoldipine
,4054203,terminal elimination half-life,The terminal elimination half-life in plasma was similar for both drugs with a mean of 2 h.,The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4054203/),h,2,14468,DB00401,Nisoldipine
,27041124,relative bioavailability,"Following single oral administration of proliposomes and SMEDDS, a relative bioavailability of 301.11% and 239.87% respectively, was achieved compared to pure nisoldipine suspension.",Comparative evaluation of proliposomes and self micro-emulsifying drug delivery system for improved oral bioavailability of nisoldipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27041124/),%,301.11,35860,DB00401,Nisoldipine
,27041124,relative bioavailability,"Following single oral administration of proliposomes and SMEDDS, a relative bioavailability of 301.11% and 239.87% respectively, was achieved compared to pure nisoldipine suspension.",Comparative evaluation of proliposomes and self micro-emulsifying drug delivery system for improved oral bioavailability of nisoldipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27041124/),%,239.87,35861,DB00401,Nisoldipine
,3345623,elimination half-life (t1/2),"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),h,4.0,42272,DB00401,Nisoldipine
,3345623,systemic clearance (CL),"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),[l] / [min],0.83,42273,DB00401,Nisoldipine
,3345623,volume of distribution,"After intravenous infusion, elimination half-life (t1/2) was 4.0 +/- 2.3 hours, systemic clearance (CL) was 0.83 +/- 0.17 L/min, and volume of distribution was 1.6 +/- 0.6 L/kg.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),[l] / [kg],1.6,42274,DB00401,Nisoldipine
,3345623,t1/2,"After oral nisoldipine, t1/2 was 3.8 +/- 1.3 hours and systemic availability was 3.9% +/- 3.5%.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),h,3.8,42275,DB00401,Nisoldipine
,3345623,systemic availability,"After oral nisoldipine, t1/2 was 3.8 +/- 1.3 hours and systemic availability was 3.9% +/- 3.5%.",Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),%,3.9,42276,DB00401,Nisoldipine
,3345623,Systemic availability,Systemic availability increased to 5.7% +/- 2.8%.,Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345623/),%,5.7,42277,DB00401,Nisoldipine
,32031412,globule size,The experimental results indicated homogeneity of the nanoemulsion with globule size of 62.35 ± 2.55 nm and PDI value of 0.108 ± 0.01 with negative zeta potential (-26.2 ± 3.6 mV).,"Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32031412/),nm,62.35,46620,DB00401,Nisoldipine
,32031412,PDI,The experimental results indicated homogeneity of the nanoemulsion with globule size of 62.35 ± 2.55 nm and PDI value of 0.108 ± 0.01 with negative zeta potential (-26.2 ± 3.6 mV).,"Enhanced bioavailability and antihypertensive activity of nisoldipine loaded nanoemulsion: optimization, cytotoxicity and uptake across Caco-2 cell line, pharmacokinetic and pharmacodynamic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32031412/),,0.108,46621,DB00401,Nisoldipine
,12483453,C(max),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[ng] / [ml],3.9,47136,DB00401,Nisoldipine
,12483453,C(max),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[ng] / [ml],0.7,47137,DB00401,Nisoldipine
,12483453,AUC(0-24),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[h·ng] / [ml],51.5,47138,DB00401,Nisoldipine
,12483453,AUC(0-24),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[h·ng] / [ml],9.4,47139,DB00401,Nisoldipine
,12483453,Cl/f,"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],3.6,47140,DB00401,Nisoldipine
,12483453,Cl/f,"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],18.7,47141,DB00401,Nisoldipine
,12483453,Cl/f,The Cl/f value of (+)-N was lower (Mann-Whitney test) in patients with DM: 6.0 (4.3-7.5) l h(-1) kg(-1) versus 3.6 (1.9-5.4) l h(-1) kg(-1).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],6.0,47142,DB00401,Nisoldipine
,12483453,Cl/f,The Cl/f value of (+)-N was lower (Mann-Whitney test) in patients with DM: 6.0 (4.3-7.5) l h(-1) kg(-1) versus 3.6 (1.9-5.4) l h(-1) kg(-1).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],3.6,47143,DB00401,Nisoldipine
,12483453,Cl/f,"The same observation was made for the (-)-N, with Cl/f reaching 38.8 (26.8-51.0) l h(-1) kg(-1) and 18.7 (11.7-25.7) l h(-1) kg(-1) for the non-diabetic and DM groups, respectively.",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],38.8,47144,DB00401,Nisoldipine
,12483453,Cl/f,"The same observation was made for the (-)-N, with Cl/f reaching 38.8 (26.8-51.0) l h(-1) kg(-1) and 18.7 (11.7-25.7) l h(-1) kg(-1) for the non-diabetic and DM groups, respectively.",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],18.7,47145,DB00401,Nisoldipine
,12483453,plasma concentrations,The data also demonstrated that the plasma concentrations of noradrenaline 30 min after N administration were lower (P < 0.05) in diabetic (mean 2.86 pmol ml(-1)) than in non-diabetic patients (4.80 pmol ml(-1)).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),pm,2.86,47146,DB00401,Nisoldipine
,12483453,plasma concentrations,The data also demonstrated that the plasma concentrations of noradrenaline 30 min after N administration were lower (P < 0.05) in diabetic (mean 2.86 pmol ml(-1)) than in non-diabetic patients (4.80 pmol ml(-1)).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[pM] / [ml],4.80,47147,DB00401,Nisoldipine
,25830370,PDI,"The optimal ND-SLN formulation had particle size of 104.4 ± 2.13 nm, PDI of 0.241 ± 0.02 and EE of 89.84 ± 0.52%.",Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25830370/),,0.241,59736,DB00401,Nisoldipine
,25830370,EE,"The optimal ND-SLN formulation had particle size of 104.4 ± 2.13 nm, PDI of 0.241 ± 0.02 and EE of 89.84 ± 0.52%.",Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25830370/),%,89.84,59737,DB00401,Nisoldipine
,29688077,oral bioavailability,Nisoldipine (ND) has low oral bioavailability (5%) due to first-pass metabolism.,"Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29688077/),%,5,61546,DB00401,Nisoldipine
,29688077,EE,"Size, ZP and EE of optimized NLCs were found to be 110.4 ± 2.95 nm, -29.4 ± 2.05 mV and 97.07 ± 2.27%, respectively.","Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29688077/),,97,61547,DB00401,Nisoldipine
,20822671,limit of detection,And the limit of detection is 1.5 ng/mL.,Preparation of a novel glycidyl methacrylate-based monolith and its application for the determination of m-nisoldipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20822671/),[ng] / [ml],1.5,71533,DB00401,Nisoldipine
,9112062,maximum reduction (Emax),"The mean maximum reduction (Emax) relative to baseline was about 36.4% and 37.7% (DBP, supine and standing) and 27.9% and 29.2% (SBP, supine and standing), respectively.",Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),%,36.4,74403,DB00401,Nisoldipine
,9112062,maximum reduction (Emax),"The mean maximum reduction (Emax) relative to baseline was about 36.4% and 37.7% (DBP, supine and standing) and 27.9% and 29.2% (SBP, supine and standing), respectively.",Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),%,37.7,74404,DB00401,Nisoldipine
,9112062,maximum reduction (Emax),"The mean maximum reduction (Emax) relative to baseline was about 36.4% and 37.7% (DBP, supine and standing) and 27.9% and 29.2% (SBP, supine and standing), respectively.",Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),%,27.9,74405,DB00401,Nisoldipine
,9112062,maximum reduction (Emax),"The mean maximum reduction (Emax) relative to baseline was about 36.4% and 37.7% (DBP, supine and standing) and 27.9% and 29.2% (SBP, supine and standing), respectively.",Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),%,29.2,74406,DB00401,Nisoldipine
,9112062,plasma concentration,The mean nisoldipine plasma concentration corresponding to 50% of the maximum effect (EC50) ranged between 0.99 and 2.62 micrograms.l-1 with a pronounced interindividual variability (% CV) of 89.5-108.8%.,Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),[μg] / [l],0.99 and 2.62,74407,DB00401,Nisoldipine
,9112062,maximum effect (EC50),The mean nisoldipine plasma concentration corresponding to 50% of the maximum effect (EC50) ranged between 0.99 and 2.62 micrograms.l-1 with a pronounced interindividual variability (% CV) of 89.5-108.8%.,Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),[μg] / [l],0.99 and 2.62,74408,DB00401,Nisoldipine
,9112062,Cmax,Mean Cmax values after administration of the 30 and 40 mg NCC together with food were 4.5 and 7.5 micrograms.,Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),μg,4.5,74409,DB00401,Nisoldipine
,9112062,Cmax,Mean Cmax values after administration of the 30 and 40 mg NCC together with food were 4.5 and 7.5 micrograms.,Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),μg,7.5,74410,DB00401,Nisoldipine
,9112062,Cmax,After administration of the 10 mg solution with a mean Cmax of 8.7 micrograms.,Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112062/),μg,8.7,74411,DB00401,Nisoldipine
,1634646,oral clearance,"No significant difference existed in oral clearance (L/h/kg) when analyzed for equivalence across the four doses: 8.21 +/- 3.47 (5 mg), 11.84 +/- 13.85 (10 mg), 11.48 +/- 7.49 (20 mg), and 10.36 +/- 5.49 (30 mg).",Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634646/),[l] / [h·kg],8.21,82755,DB00401,Nisoldipine
,1634646,oral clearance,"No significant difference existed in oral clearance (L/h/kg) when analyzed for equivalence across the four doses: 8.21 +/- 3.47 (5 mg), 11.84 +/- 13.85 (10 mg), 11.48 +/- 7.49 (20 mg), and 10.36 +/- 5.49 (30 mg).",Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634646/),[l] / [h·kg],11.84,82756,DB00401,Nisoldipine
,1634646,oral clearance,"No significant difference existed in oral clearance (L/h/kg) when analyzed for equivalence across the four doses: 8.21 +/- 3.47 (5 mg), 11.84 +/- 13.85 (10 mg), 11.48 +/- 7.49 (20 mg), and 10.36 +/- 5.49 (30 mg).",Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634646/),[l] / [h·kg],11.48,82757,DB00401,Nisoldipine
,1634646,oral clearance,"No significant difference existed in oral clearance (L/h/kg) when analyzed for equivalence across the four doses: 8.21 +/- 3.47 (5 mg), 11.84 +/- 13.85 (10 mg), 11.48 +/- 7.49 (20 mg), and 10.36 +/- 5.49 (30 mg).",Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634646/),[l] / [h·kg],10.36,82758,DB00401,Nisoldipine
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB00401,Nisoldipine
,24898424,AUC ratio,"According to the developed method, the AUC ratio of felodipine was 2.50 and its coefficient of variation (CV) was 45%, which agreed well with the observed AUC ratio of 2.48 and CV of 51%.",Prediction of the extent and variation of grapefruit juice-drug interactions from the pharmacokinetic profile in the absence of grapefruit juice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24898424/),,2.50,100635,DB00401,Nisoldipine
,24898424,AUC ratio,"According to the developed method, the AUC ratio of felodipine was 2.50 and its coefficient of variation (CV) was 45%, which agreed well with the observed AUC ratio of 2.48 and CV of 51%.",Prediction of the extent and variation of grapefruit juice-drug interactions from the pharmacokinetic profile in the absence of grapefruit juice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24898424/),,2.48,100636,DB00401,Nisoldipine
,3402524,elimination half-life,"After i.v. nisoldipine, the elimination half-life was 9.7 h in control subjects and 16.6 h in the cirrhotics.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),h,9.7,105352,DB00401,Nisoldipine
,3402524,elimination half-life,"After i.v. nisoldipine, the elimination half-life was 9.7 h in control subjects and 16.6 h in the cirrhotics.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),h,16.6,105353,DB00401,Nisoldipine
,3402524,volume of distribution,"The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),[l] / [kg],4.1,105354,DB00401,Nisoldipine
,3402524,volume of distribution,"The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),[l] / [kg],6.4,105355,DB00401,Nisoldipine
,3402524,total systemic clearance,"The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),[ml] / [min],847,105356,DB00401,Nisoldipine
,3402524,total systemic clearance,"The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),[ml] / [min],494,105357,DB00401,Nisoldipine
,3402524,systemic availability,"On oral nisoldipine, systemic availability was fourfold higher in patients with cirrhosis: 14.7% versus 3.7%.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),%,14.7,105358,DB00401,Nisoldipine
,3402524,systemic availability,"On oral nisoldipine, systemic availability was fourfold higher in patients with cirrhosis: 14.7% versus 3.7%.",Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3402524/),%,3.7,105359,DB00401,Nisoldipine
,2130609,flow rate,A mobile phase of methanol-KH2PO4 with a flow rate of 1 ml/min was used.,Pharmacokinetics of m-nisoldipine in rabbits and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[ml] / [min],1,107378,DB00401,Nisoldipine
,2130609,T 1/2 alpha,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,4.3,107379,DB00401,Nisoldipine
,2130609,T 1/2 beta,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,63.6,107380,DB00401,Nisoldipine
,2130609,Vd,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[l] / [kg],0.805,107381,DB00401,Nisoldipine
,2130609,Cl,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[ml] / [kg·min],9,107382,DB00401,Nisoldipine
,2130609,T 1/2 alpha,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,5.0,107383,DB00401,Nisoldipine
,2130609,T 1/2 beta,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,78.3,107384,DB00401,Nisoldipine
,2130609,Vd,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[l] / [kg],1.191,107385,DB00401,Nisoldipine
,2130609,Cl,"The pharmacokinetic parameters were: T 1/2 alpha = 4.3 min, T 1/2 beta = 63.6 min, Vd = 0.805 L/kg, Cl = 9 ml/(min.kg) in rats; T 1/2 alpha = 5.0 min, T 1/2 beta = 78.3 min, Vd = 1.191 L/kg, Cl = 11 ml/(min.kg) in rabbits.",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[ml] / [kg·min],11,107386,DB00401,Nisoldipine
,2130609,T 1/2,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,84.8,107387,DB00401,Nisoldipine
,2130609,Tmax,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),min,31.2,107388,DB00401,Nisoldipine
,2130609,Cmax,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[μg] / [l],49.97,107389,DB00401,Nisoldipine
,2130609,Vd,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[l] / [kg],0.792,107390,DB00401,Nisoldipine
,2130609,Cl,"The pharmacokinetics for m-Nis after ig 200 micrograms/kg to rats described one-compartment model with parameters: T 1/2 = 84.8 min, Tmax = 31.2 min, Cmax = 49.97 micrograms/L, Vd = 0.792 L/kg and Cl = 25 ml/(min.kg).",Pharmacokinetics of m-nisoldipine in rabbits and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2130609/),[ml] / [kg·min],25,107391,DB00401,Nisoldipine
,23892657,flow rate,"After m-nisoldipine racemic administration to beagle dogs, samples of m-nisoldipine enantiomers in beagle dog plasma were separated and determined on a ULTRON ES-OVM column (150 × 4.6 mm, 5 μm) at 20°C with a mobile phase consisted of methanol-acetonitrile-ammonium acetate (pH 7.0; 2mM) (15:15:70, v/v/v) at a flow rate of 0.8 mL/min.",Studies on separation and pharmacokinetics of m-nisoldipine enantiomers in beagle dog plasma by LC/MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23892657/),[ml] / [min],0.8,117513,DB00401,Nisoldipine
,8917062,areas under the concentration-time curve (AUC0-tn),"Geometric means for areas under the concentration-time curve (AUC0-tn) normalized to a 20-mg dose were 1.6 micrograms/L/h (95% confidence intervals, 0.6-3.8 micrograms/L/h) in the patients compared with 15.2 (10.7-21.6) micrograms/L/h in control subjects (p < 0.002).",Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917062/),[μg] / [h·l],1.6,129374,DB00401,Nisoldipine
,8917062,areas under the concentration-time curve (AUC0-tn),"Geometric means for areas under the concentration-time curve (AUC0-tn) normalized to a 20-mg dose were 1.6 micrograms/L/h (95% confidence intervals, 0.6-3.8 micrograms/L/h) in the patients compared with 15.2 (10.7-21.6) micrograms/L/h in control subjects (p < 0.002).",Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917062/),[μg] / [h·l],15.2,129375,DB00401,Nisoldipine
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB00401,Nisoldipine
,9784933,absolute bioavailability,"Although nisoldipine is almost completely absorbed, its absolute bioavailability from the CC tablet is only 5.5%, as a result of significant first-pass metabolism in the gut and liver.",Clinical pharmacokinetics of nisoldipine coat-core. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784933/),%,5.5,154456,DB00401,Nisoldipine
,3196402,half-lives,The radioactivity was eliminated from plasma with half-lives between 42 h and 54 h within an observation period up to 3 days.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),h,42,181948,DB00401,Nisoldipine
,3196402,half-lives,The radioactivity was eliminated from plasma with half-lives between 42 h and 54 h within an observation period up to 3 days.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),h,54,181949,DB00401,Nisoldipine
,3196402,bioavailability,The bioavailability was estimated at 3.4% in rats and 11.7% in dogs.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),%,3.4,181950,DB00401,Nisoldipine
,3196402,bioavailability,The bioavailability was estimated at 3.4% in rats and 11.7% in dogs.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),%,11.7,181951,DB00401,Nisoldipine
,3196402,free fractions,[14C]nisoldipine was highly bound to plasma proteins with free fractions of 0.9-2.9%.,"Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196402/),%,0.9-2.9,181952,DB00401,Nisoldipine
,16567136,flow rate,"Separation of analyte and internal standard (I.S.) was performed on a Symmetry RP-C(18) analytic column (50 mm x 4.6 mm, 3.5 microm) with a mobile phase consisting of acetonitrile-water (80:20, v/v) at a flow rate of 0.5 ml/min.",Validated LC-MS-MS method for determination of m-nisoldipine polymorphs in rat plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16567136/),[ml] / [min],0.5,184710,DB00401,Nisoldipine
,2620681,Maximal coronary dilation,Maximal coronary dilation amounted to 20 +/- 9% (4th min) in group I and to 18 +/- 9% (15th min) in group II.,Coronary vasodilation with dihydropyridines--a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620681/),%,20,192636,DB00401,Nisoldipine
,2620681,Maximal coronary dilation,Maximal coronary dilation amounted to 20 +/- 9% (4th min) in group I and to 18 +/- 9% (15th min) in group II.,Coronary vasodilation with dihydropyridines--a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620681/),%,18,192637,DB00401,Nisoldipine
,2620681,maximal plasma concentrations,In order to compare the pharmacokinetic properties of these compounds the dilation of the 'normal' coronary segments was correlated with the respective drug plasma levels; maximal plasma concentrations averaged 62 +/- 21 ng ml-1 (7th min) in group I and 17 +/- 7 ng ml-1 (4th min) in group II respectively.,Coronary vasodilation with dihydropyridines--a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620681/),[ng] / [ml],62,192638,DB00401,Nisoldipine
,2620681,maximal plasma concentrations,In order to compare the pharmacokinetic properties of these compounds the dilation of the 'normal' coronary segments was correlated with the respective drug plasma levels; maximal plasma concentrations averaged 62 +/- 21 ng ml-1 (7th min) in group I and 17 +/- 7 ng ml-1 (4th min) in group II respectively.,Coronary vasodilation with dihydropyridines--a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620681/),[ng] / [ml],17,192639,DB00401,Nisoldipine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,1.50,192764,DB00401,Nisoldipine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,2.06,192765,DB00401,Nisoldipine
,3203043,systemic clearance,"2. After high-dose nisoldipine, systemic clearance was 0.99 +/- 0.16 1 min-1, volume of distribution was 5.8 +/- 1.5 1 kg-1 and elimination half-life was 10.7 +/- 2.4 h.",The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203043/),[1] / [min],0.99,203761,DB00401,Nisoldipine
,3203043,volume of distribution,"2. After high-dose nisoldipine, systemic clearance was 0.99 +/- 0.16 1 min-1, volume of distribution was 5.8 +/- 1.5 1 kg-1 and elimination half-life was 10.7 +/- 2.4 h.",The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203043/),[1] / [kg],5.8,203762,DB00401,Nisoldipine
,3203043,elimination half-life,"2. After high-dose nisoldipine, systemic clearance was 0.99 +/- 0.16 1 min-1, volume of distribution was 5.8 +/- 1.5 1 kg-1 and elimination half-life was 10.7 +/- 2.4 h.",The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203043/),h,10.7,203763,DB00401,Nisoldipine
,15693192,limit of detection,The limit of detection is 0.2 ng/mL.,High-performance liquid chromatography-electrospray ionization mass spectrometric determination of nisoldipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15693192/),[ng] / [ml],0.2,214319,DB00401,Nisoldipine
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,371.35,225426,DB00401,Nisoldipine
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,270.20,225427,DB00401,Nisoldipine
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,360.00,225428,DB00401,Nisoldipine
,11589462,AUC(0-24) (+)/(-) ratio,The enantioselective pilot study on the kinetic disposition of nisoldipine administered in the racemic form to a hypertensive patient using a multiple dose regimen revealed the accumulation of the (+)-enantiomer with an AUC(0-24) (+)/(-) ratio of approximately 8.,Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,8,225429,DB00401,Nisoldipine
,30079887,flow rate,"The analytes were separated on a Phenomenex Luna C18 column (150 mm × 2.0 mm, 3 µm) at 40 °C using isocratic mobile phase consisting of 0.2% formic acid-methanol (13 : 87, v/v) at a flow rate of 0.2 mL/min.",Determination of lacidipine in human plasma by LC-MS/MS: Application in a bioequivalence study . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079887/),[ml] / [min],0.2,226270,DB00401,Nisoldipine
,30079887,m/,"The selected reaction monitoring of transitions was m/z 456.2 → 354.2 for lacidipine and m/z 389.2 → 315.0 for IS, respectively.",Determination of lacidipine in human plasma by LC-MS/MS: Application in a bioequivalence study . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079887/),,456.2,226271,DB00401,Nisoldipine
,30079887,m/,"The selected reaction monitoring of transitions was m/z 456.2 → 354.2 for lacidipine and m/z 389.2 → 315.0 for IS, respectively.",Determination of lacidipine in human plasma by LC-MS/MS: Application in a bioequivalence study . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079887/),,354.2,226272,DB00401,Nisoldipine
,30079887,m/z,"The selected reaction monitoring of transitions was m/z 456.2 → 354.2 for lacidipine and m/z 389.2 → 315.0 for IS, respectively.",Determination of lacidipine in human plasma by LC-MS/MS: Application in a bioequivalence study . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079887/),,389.2,226273,DB00401,Nisoldipine
,30079887,m/z,"The selected reaction monitoring of transitions was m/z 456.2 → 354.2 for lacidipine and m/z 389.2 → 315.0 for IS, respectively.",Determination of lacidipine in human plasma by LC-MS/MS: Application in a bioequivalence study . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30079887/),,315.0,226274,DB00401,Nisoldipine
,1777376,apparent liver blood flow,3. The addition of nisoldipine was also associated with significant changes in apparent liver blood flow (measured by indocyanine green clearance) from 1.4 to 2.4 l min-1 in the atenolol group and from 1.3 to 2.3 l min-1 in the propranolol group.,The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777376/),[l] / [min],1.4 to 2.4,227822,DB00401,Nisoldipine
,1777376,apparent liver blood flow,3. The addition of nisoldipine was also associated with significant changes in apparent liver blood flow (measured by indocyanine green clearance) from 1.4 to 2.4 l min-1 in the atenolol group and from 1.3 to 2.3 l min-1 in the propranolol group.,The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777376/),[l] / [min],1.3 to 2.3,227823,DB00401,Nisoldipine
,9266290,absolute bioavailability,"While the absolute bioavailability of the drug in the coat-core tablet was 5.5%, its relative bioavailability was greater by 1.5-fold compared to the immediate-release tablet.",Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9266290/),%,5.5,245095,DB00401,Nisoldipine
,18855612,F(G),"F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.07,268540,DB00401,Nisoldipine
,18855612,F(G),"F(G) values ranged from 0.07 to 0.92 for lovastatin and quinidine, respectively.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.92,268541,DB00401,Nisoldipine
< or =,18855612,F(G),"An area of high intestinal extraction (F(G) < or = 0.25) is identified as problematic, as availability of conclusive data is limited in this area.",Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18855612/),,0.25,268542,DB00401,Nisoldipine
